L597V BRAF mutations are acquired somatically in human cancer samples and are frequently coincident with RAS mutations. Germline L597V BRAF mutations are also found in several autosomal dominant developmental conditions known as RASopathies, raising the important question of how the same mutation can contribute to both pathologies. Using a conditional knock-in mouse model, we show that endogenous expression of L597V Braf leads to approximately twofold elevated Braf kinase activity and weak activation of the Mek/Erk pathway. This is associated with induction of RASopathy hallmarks including cardiac abnormalities and facial dysmorphia but is not sufficient for tumor formation. We combined L597V Braf with G12D Kras and found that L597V Braf modified G12D Kras oncogenesis such that fibroblast transformation and lung tumor development were more reminiscent of that driven by the high-activity V600E Braf mutant. Mek/Erk activation levels were comparable with those driven by V600E Braf in the double-mutant cells, and the gene expression signature was more similar to that induced by V600E Braf than G12D Kras. However, unlike V600E Braf, Mek/Erk pathway activation was mediated by both Craf and Braf, and ATP-competitive RAF inhibitors induced paradoxical Mek/ Erk pathway activation. Our data show that weak activation of the Mek/Erk pathway underpins RASopathies, but in cancer, L597V Braf epistatically modifies the transforming effects of driver oncogenes.
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The RAS/RAF/MEK/ERK signaling pathway is a critical mediator of cell growth signals in multiple organisms and cell types. Dysregulation of this pathway is a key characteristic of tumor cells, and components of the pathway are mutational targets in human cancer (Pearson et al. 2001; Davies et al. 2002; Malumbres and Barbacid 2003) .
In particular, oncogenic BRAF and RAS mutations are detected in ;7% and ;30% of samples, respectively, and their common ability to activate the downstream MEK/ ERK pathway is thought to account at least in part for the transforming effects of these oncogenes (Davies et al. 2002; Malumbres and Barbacid 2003) . Germline mutations in components of the RAS/RAF/MEK/ERK pathway, including BRAF and RAS, are also detected in a group of newly described developmental disorders collectively known as ''RASopathies'' (Tidyman and Rauen 2009; Rauen et al. 2011) . RASopathies include Noonan syndrome (NS), LEOPARD syndrome (LS), Neurofibromatosis type 1 (NF1), Costello syndrome (CS), and cardio-facio-cutaneous syndrome (CFC) and have many overlapping features, including craniofacial abnormalities, cardiac malfunctions, and cutaneous, muscular, and ocular impairments with some increased risk of cancer (Tidyman and Rauen 2009; Rauen et al. 2011) .
Of the BRAF mutations detected in human cancer, the high-activity common, being detected in >90% of cases (Davies et al. 2002) . However, several other mutations are detected at a lower frequency and have been categorized into high, intermediate, or impaired depending on the level of kinase activity they possess (Wan et al. 2004 ). Whereas V600E BRAF mutations are mutually exclusive with RAS mutations in human cancer samples, the intermediateand impaired-activity BRAF mutations are significantly coincident with RAS or other oncogenic driver mutations (http://www.sanger.ac.uk/genetics/CGP/cosmic), suggesting that they may be cooperating rather than driver mutations. In RASopathies, BRAF mutations are detected in ;75% of mutation-positive CFC patients and at lower frequencies in NS and LS patients (Rodriguez-Viciana et al. 2006; Sarkozy et al. 2009 ). All of the BRAF mutations are non-V600E BRAF. The majority fall into the high-or intermediate-activity class (Rodriguez-Viciana et al. 2006) , with only seven also being found in human cancer samples; namely, G469E, F468S, L485F, F595L, V600G, and K601E in CFC patients (Rodriguez-Viciana et al. 2006; Champion et al. 2011) , with the intermediateactivity L597V mutation being detected in both NS and CFC patients (Sarkozy et al. 2009; Pierpont et al. 2010) .
How the same mutations can promote developmental abnormalities when constitutively expressed but cancer when acquired somatically is a critical question to address and is likely related to mechanisms of downstream MEK/ERK pathway activation under different contexts. High-activity mutants, such as V600E BRAF, have activity greater than oncogenic RAS-induced WT BRAF and are known to induce tumor development through their intrinsic ability to hyperactivate the MEK/ERK pathway (Davies et al. 2002; Karasarides et al. 2004 ). The situation is more complex with lower-activity BRAF mutants. Although impaired-activity mutants have lower activity than WT BRAF, they induce ERK activation through the formation of heterodimers with CRAF, leading to its activation (Wan et al. 2004; Kamata et al. 2010) . Through analysis of the impaired-activity
D594A
Braf mutant in mice, we demonstrated that transactivation of Craf in this context was insufficient to drive tumor development per se (Kamata et al. 2010) , although, when coexpressed with oncogenic Ras, a cooperating role in tumor development was revealed (Heidorn et al. 2010) . Intermediate-activity mutants have activity in between oncogenic RAS-induced WT BRAF and WT BRAF and, following overexpression in COS cells, have been shown to induce MEK/ ERK activation but to a lower level than high-activity mutants (Wan et al. 2004) . CRAF was also transactivated by these mutants in COS cells, although siRNA depletion studies showed that BRAF but not CRAF was responsible for ERK activation in these situations (Wan et al. 2004) . Whether mutants of this class are able to drive tumor development in vivo has not yet been addressed, nor has their role in inducing RASopathy syndromes.
Apart from the MEK/ERK pathway, oncogenic RAS can activate multiple downstream signaling pathways, including the phosphatidylinositol 3-kinase (PI3K)/AKT and RalGDS signaling pathways (Malumbres and Barbacid 2003) . Of these various pathways, studies in mice have shown a particular dependency on the MEK/ERK pathway for tumor maintenance driven by oncogenic RAS, despite the fact that this pathway is only weakly activated by the oncogene (Tuveson et al. 2004 ). In two separate reports, treatment of mice with MEK inhibitors showed significant regression of oncogenic Kras-driven tumors in the lung (Ji et al. 2007; Engelman et al. 2008) , although a synergistic effect of combined PI3K inhibition was demonstrated in one of these reports (Engelman et al. 2008) . Recent studies using knockout mice have also shown a critical role for the Raf/Mek/Erk pathway in lung tumor initiation downstream from oncogenic Kras (Blasco et al. 2011; Karreth et al. 2011) . Elimination of both Erk isoforms or both Mek isoforms completely blocked tumor development. However, while knockout of Craf prevented lung tumor development, Braf knockout had no significant effect, indicating that Braf cannot compensate for the loss of Craf and that oncogenic Kras elicits its oncogenic effects through Craf. Consistent with this, oncogenic RAS has been shown to signal exclusively through CRAF to MEK in melanoma cell lines (Dumaz et al. 2006) , and Craf has been shown to be required for tumor initiation and maintenance in the DMBA/TPA skin tumorigenesis model in which tumor development is driven by the acquisition of ras mutations ).
All of the above data reinforce the rationale for targeting RAS/RAF/MEK/ERK as an anti-cancer strategy, an initiative that has been under way for several years now. Although targeted therapies against RAS have largely failed (Basso et al. 2006) , the availability of selective chemical inhibitors against RAF, MEK, and ERK have provided new therapeutic opportunities (Montagut and Settleman 2009) . RAF inhibitors have made the most progress in the clinic, with the ATP-competitive inhibitor vemurafenib (PLX4032) showing remarkable efficacy in the treatment of melanomas with the V600E BRAF mutation (Chapman et al. 2011) . The drug increased rates of overall and progression-free survival in patients with previously untreated melanoma, although resistance to the drug eventually emerged (Johannessen et al. 2010; Nazarian et al. 2010; Chapman et al. 2011; Su et al. 2012) . Despite this extraordinary success, the ability of a given cancer to respond to vemurafenib and other similar RAF inhibitors is dependent on BRAF mutation status (Hatzivassiliou et al. 2010; Heidorn et al. 2010; Poulikakos et al. 2010) . In melanomas with the V600E BRAF mutation, levels of RAS activation are low, and these drugs bind to BRAF monomers, inhibiting their activity (Hatzivassiliou et al. 2010; Heidorn et al. 2010; Poulikakos et al. 2010) . However, in WT BRAF cells, activated RAS promotes dimerization of members of the RAF family, and vemurafenib has been shown to activate signaling through the MEK/ERK pathway by transactivating CRAF (Hatzivassiliou et al. 2010; Heidorn et al. 2010; Poulikakos et al. 2010 ). This has been hypothesized to explain why ;18% of patients administered with vemurafenib develop squamous cell carcinoma of the skin or keratoacanthoma, with them arising from vemurafenib-induced MEK/ERK pathway activation in cells that have WT BRAF but active RAS (Chapman et al. 2011; Su et al. 2012) . RAF/ MEK inhibitors also offer huge potential for the treatment of RASopathies, and the suppression of RASopathy symptoms in animal models by MEK inhibitors is highly encouraging in this regard (Schuhmacher et al. 2008; Anastasaki et al. 2009; Sarkozy et al. 2009; Rauen et al. 2011) . As with cancers, it will be important to understand the mechanisms underpinning RAS/RAF/MEK/ERK pathway deregulation in individual RASopathy patients as a corollary to the implementation of these novel therapies in the clinic.
We focused our efforts on understanding the contribution of each class of BRAF mutation to cancer and RASopathies by creating conditional knock-in mouse models with the view to informing better treatments for patients suffering from these diseases. Here, we generated a conditional knock-in mouse for the intermediate activity mutant 
Results

Generation of L597V
Braf-expressing mice
We used a strategy for the generation of Cre-regulated, conditional knock-in LSL-Braf L597V mice (Fig. 1A ) similar to that previously reported for LSL-Braf V600E (Mercer et al. 2005) and LSL-Braf D594A (Mercer et al. 2005 ; Heidorn et al. (E) Gross facial appearance of 3-moold +/+ and +/LV female mice illustrating the blunt nose of mutant animals (arrowhead). (F) Enlarged heart. H&E-stained crosssections of hearts of 3-mo-old mice are shown. Bars, 2 mm. The bar chart indicates the heart weight/body weight ratio of 3-moold +/+ (n = 6) and +/LV (n = 3) mice. (*) P < 0.01, Student's t-test. (G) Wheat germ agglutinin-stained cross-sections of cardiomyocytes. Bars, 100 mm. Cross-sectional areas were measured (n = 3 samples per genotype, with 100 cells counted per sample), and the average areas are given below for each genotype. Braf from one allele of Braf was achieved by intercrossing Braf +/LSL-L597V heterozygous mice with mice heterozygous for the CMV-Cre transgene (Schwenk et al. 1995) . PCR genotyping was used to confirm inheritance of the LSL-Braf L597V allele as well as Cre-mediated recombination to form the Lox-Braf L597V allele (Supplemental Fig.  S1 ). On a predominantly C57BL6J background (at least five backcross generations), Braf +/Lox-L597V (+/LV) animals were born alive at the expected Mendelian ratio, but some animals were lost after weaning, with ;70% surviving to adulthood (Fig. 1B) .
Mice expressing endogenous
L597V
Braf develop RASopathy hallmarks
All surviving +/LV animals were ;10%-20% reduced in weight compared with controls ( Fig. 1C ). In addition, these animals showed multiple NS/CFC phenotypes, including short stature ( Fig. 1D ), facial dysmorphia ( Fig.  1E) , and cardiac enlargement with substantial thickening of the ventricular wall and septum (Fig. 1F ). Cardiomyocyte cross-sectional area was increased by ;20% in +/LV mice, indicative of cardiac hypertrophy (Fig. 1G ). The surviving +/LV animals developed a spectrum of other pathologies with variable penetrance (Supplemental Table S1). Although they did not develop any signs of advanced cancer, they showed a predisposition to the development of benign tumors, including skin papillomas and intestinal polyps, when aged (Supplemental Fig. S2 ; Supplemental Table S1 ).
L597V
Braf is a weak activator of the Mek/Erk pathway but does not transform MEFs
To further investigate the transforming potential of L597V Braf, we induced expression of the mutant protein in MEFs by treating Braf +/LSL-L597V primary MEFs with adenoviral-Cre (AdCre) or adenoviral-bgal (Adbgal). As comparisons, Braf +/+ and Braf +/LSL-V600E MEFs were simultaneously treated. PCR analysis showed that ;50% recombination of the LSL-L597V and LSL-V600E alleles occurred within 24 h of AdCre treatment, and recombination was virtually complete by 72 h (Supplemental Fig.  S3 ). Previous studies have shown that L597V BRAF is ;70-fold more active than WT BRAF, while V600E BRAF is ;500-fold more active when overexpressed (Wan et al. 2004 ). To assess the activity of L597V Braf when endogenously expressed from one allele of Braf, as occurs in human cancer, we performed Braf kinase assays of MEF protein lysates.
V600E Braf expression induced approximately eightfold elevated Braf activity, whereas
Braf expression elevated Braf activity by approximately twofold compared with WT Braf (Fig. 2A) . While V600E Braf expression gave rise to significant induction of phospho-Mek, phospho-Mek was only slightly elevated in LV cells compared with controls (Fig. 2B ). However, phospho-Erk reached levels similar to that in VE cells and was not significantly different (Fig. 2B ). To explain this paradox, we analyzed the expression of Sprouty2 and Dusp6, negative regulators of the Mek/Erk pathway (Packer et al. 2009; Pratilas et al. 2009) , and found that both were significantly induced by V600E Braf but not by L597V Braf (Fig. 2B ). The induction of Dusp6 could explain, in part, the equivalent levels of phospho-Erk in the VE and LV cells, and indeed, we found that phospho-Erk levels are raised in
V600E
Braf cells when the expression of Dusp6 is down-regulated by siRNA knockdown (Supplemental Fig.  S4A ). As further confirmation of greater Mek/Erk output by V600E Braf, we also detected higher levels of p90 RSK phosphorylation in VE cells compared with LV and wildtype cells (Supplemental Fig. S4B ). Distinct morphological transformation of primary VE MEFs was observed, as previously reported (Mercer et al. 2005) , whereas LV MEFs were not transformed and were similar in morphology to control MEFs (Fig.  2C ). In addition, VE primary MEFs had an enhanced growth rate ( Fig. 2D ) and immortalized at early passage number (Fig. 2E ), while LV cells had growth and immortalization profiles similar to control MEFs (Fig. 2D,E) . Overall, these data show that L597V Braf is able to induce weakly elevated signaling through the Mek/Erk pathway, and while this is sufficient to induce RASopathy hallmarks, it is not enough to transform primary fibroblasts.
L597V Braf does not induce lung tumor growth in vivo
To examine the cancer phenotype more directly, we focused on the lung, since L597V BRAF mutations are more prevalent in human non-small-cell lung cancer (NSCLC) than any other cancer (http://www.sanger.ac.uk/perl/ genetics/CGP/cosmic). The lungs of Braf +/Lox-L597V mice with and without the CMV-Cre transgene were examined by H&E staining. In both cases, no histopathological changes were observed compared with controls (Fig. 3A) . We also examined the consequences of AdCre delivery to the lungs of Braf +/LSL-L597V mice by nasal inhalation compared with the lungs of Braf +/+ and Braf
mice. While AdCre induced the rapid formation of multiple benign adenomas in the Braf +/LSL-V600E mice (Fig. 3B ), as previously reported (Dankort et al. 2007) , there were no histopathological changes in the Braf +/LSL-L597V lungs (Fig. 3B) . Furthermore, while AdCre delivery gave rise to significant levels of LSL-V600E recombination in the lung, AdCre-mediated LSL-L597V recombination was not detectable (Supplemental Fig. S5A ), indicating that L597V Braf expression in the lung does not give a selective growth advantage.
Constitutive expression of
V600E
Braf in mice gives rise to embryonic lethality (Mercer et al. 2005 Braf-expressing samples (Fig. 3C) . Phospho-Mek levels were slightly elevated, but to a significantly lower extent than the V600E Braf lung, whereas phospho-Erk levels were significantly higher in the L597V Braf lung than the V600E Braf lung (Fig. 3D) , presumably due to the high levels of Dusp6 induced by V600E Braf (Fig. 3D ) that can down-regulate phospho-Erk (Supplemental Fig. S4A ). This is a slightly different scenario from MEFs where phospho-Erk levels were comparable in the L597V Braf and
Braf samples (Fig. 2B) , suggesting that there may be tissue-specific differences in regulation of the Mek/Erk pathway. Overall, these data show that, as with MEFs,
L597V
Braf has weak activity toward the Mek/Erk pathway in the lung, and this is not sufficient to induce tumor development in vivo.
Braf modifies G12D Kras-induced MEF transformation L597 BRAF mutations are frequently coincident with other oncogenic driver mutations in human cancer, particularly oncogenic RAS mutations (http://www.sanger. ac.uk/perl/genetics/CGP/cosmic). Given that L597V Braf Cold
is not able to transform cells on its own (Fig. 2C) MEFs, and Cre-mediated recombination of Lox-Stop-Lox (LSL) alleles was confirmed by PCR genotyping (Supplemental Fig. S5B ). Consistent with previous observations (Tuveson et al. 2004; Mercer et al. 2005) , G12D and VE MEFs showed evidence of transformation, although the V600E Braf-driven morphology was far more distinct than that driven by G12D Kras (Fig. 4A) . Adding
Braf and
G12D
Kras mutations together led to a more striking morphological transformation than either mutation alone, and the double-mutant cells were more similar to VE cells in this regard (Fig. 4A) .
The G12D Kras and L597V Braf mutations together induced significantly higher levels of phospho-Mek than either mutation alone (Fig. 4B,C) . Phospho-Erk levels were not significantly different between the single-and double-mutant cells, presumably because of alterations in the expression of Dusps (Fig. 4B,C) . Indeed, the doublemutant MEFs had significantly higher Dusp6 levels compared with the single-mutant G12D or LV cells (Fig.  4B,C) . Sprouty2 levels were higher in the G12D/LV cells compared with the LV cells but were not significantly different between the G12D/LV and G12D cells (Fig. 4C) , suggesting that Sprouty2 expression may also be regulated by non-Mek/Erk pathways in MEFs.
Analysis of the growth of primary cells showed that G12D cells had higher growth rates than VE cells, whereas the double-mutant cells grew in between the two (Fig. 4D) . The G12D/LV MEFs underwent early immortalization, although the kinetics of immortalization was delayed in comparison with G12D cells, with them immortalizing at a passage number more similar to the VE cells (Fig. 4E) . The slower growth and immortalization of VE and G12D/LV MEFs in comparison with G12D cells may be related to the higher Mek/Erk signaling in these cells and the consequent impact on D-type cyclin expression. Indeed, we found that, although the expression of Cyclin d1 and d2 was elevated in VE, G12D, and G12D/LV cells compared with control and LV cells, Cyclin d3 was only elevated in G12D cells (Supplemental Fig. S6 ). Overall, these data show that L597V Braf enhances G12D Kras signaling through the Mek/Erk pathway, and this has the effect of partially converting G12D Kras to an oncogene more like V600E Braf.
L597V
Braf modifies G12D Kras-induced lung tumor development G12D Kras and V600E Braf induce the formation of pulmonary preneoplastic lesions with similar histopathological characteristics (Jackson et al. 2001; Dankort et al. 2007) , and both are dependent on the Erk signaling pathway for tumor maintenance (Ji et al. 2007 ). The major difference between the two is that
V600E
Braf induces more rapid tumor growth followed by the induction of senescence, whereas G12D Kras elicits faster progression to adenocarcinoma. We administered AdCre by nasal inhalation to Kras +/LSL-G12D and Braf +/LSL-V600E mice as well as doublemutant Kras +/LSL-G12D ;Braf +/LSL-L597V mice and analyzed lung tumor development at 8 and 12 wk post-AdCre treatment. Cre-mediated recombination was confirmed by PCR ( Supplemental Fig. S5A ). The VE lung had a higher tumor burden than the G12D lung, and the tumor burden for the G12D/LV lung remained similar to that driven by G12D (Fig. 5A,B) . Consistent with previous observations (Jackson et al. 2001; Dankort et al. 2007) , G12D Kras and V600E Braf induced a spectrum of preneoplastic lesions, including bronchiolar hyperplasia (BH), adenomatous alveolar hyperplasia (AAH), and adenomas, although V600E Braf induced far more adenomas and fewer AAH lesions than G12D Kras (Fig. 5A,C) . The presence of L597V Braf on top of G12D Kras generated significantly more adenomas but fewer AAH lesions (Fig. 5A,C) . Mosaic Cremediated recombination is a more frequent occurrence with multiple floxed alleles, and indeed, a lower level of recombination of the Braf LSL allele was observed in the G12D/LV lung compared with the VE lung (Supplemental Fig. S5A ). This may account in part for the observation that the G12D/LV phenotype is only partially transitioned to the VE lung phenotype (Fig. 5A-C) . While occasional adenocarcinoma transitions were observed in the G12D mice (two of 10 mice analyzed), none were observed in the VE mice (zero of 10 mice analyzed) or G12D/LV mice (zero of 11 mice analyzed). Activation of the Mek/Erk pathway and the expression of downstream Cold Spring Harbor Laboratory Press on October 19, 2017 -Published by genesdev.cshlp.org Downloaded from targets Dusp6 and Sprouty2 were enhanced by combining the L597V Braf mutation with the G12D Kras mutation (Fig. 5D) . Thus, as in MEFs,
L597V
Braf modifies G12D Krasdriven lung tumor development such that there is a partial transition to tumors with biochemical and histological features more similar to those driven by V600E Braf.
Transcriptome profiling
In order to perform a more direct assessment of the impact of L597V Braf on G12D Kras, we undertook microarray comparison of genes expressed in immortalized wild-type, LV, VE, G12D, and G12D/LV MEFs. Following microarray normalization and summarization, analysis of variance (ANOVA) with a 0.01 false discovery rate (FDR) threshold was used to identify genes significantly altered compared with wild-type controls (Supplemental Table S2 ). For all genotypes, more genes were up-regulated than were down-regulated (Fig. 6A ). There were 137 gene changes in the LV samples, 404 in the G12D samples, 492 in the G12D/LV samples, and 975 in the VE samples (Fig. 6B,C) . Thus, consistent with the morphology data (Fig. 4A) ,
L597V
Braf had a weaker molecular effect than either of the other mutations, whereas V600E Braf had the strongest molecular effect. Less than 20% of the gene expression changes observed in the LV MEFs were shared with G12D or VE MEFs, whereas ;50% of the gene changes induced by G12D were shared by VE (223 genes) (Fig. 6A,B) . Given that previous studies in melanoma cells have shown that the gene expression signature induced by V600E BRAF is attributable to signaling through the MEK/ERK pathway (Packer et al. 2009 ), these data suggest that approximately half of the gene changes induced by G12D Kras arise through signaling through this pathway, and the weak effect of L597V Braf on the Mek/Erk pathway is insufficient to induce cognate transcriptional changes.
Of the gene changes observed in the G12D/LV samples, ;40% were also found in single-mutant samples alone, predominantly within the G12D cohort (Fig. 6C,D) , indicating that the combination of the two mutations is able to mirror the molecular effects of either mutation alone to some extent, but additional molecular changes are induced on top of this. Indeed, the G12D/LV samples had more gene expression changes shared in common with VE than G12D (;65% compared with 40%) (Fig.  6C,D) , suggesting that L597V Braf may subvert some of the signaling induced by G12D Kras away from other Raseffector pathways toward the Mek/Erk pathway. In addition, ;30% of the gene changes in the G12D/LV samples were not shared with either VE or G12D (146 of 492 genes) (Fig. 6D) , suggesting that
Braf may act to regulate Mek/Erk-independent and Ras-independent signaling pathways.
Gene ontology analysis performed using GenMAPP (http://www.genmapp.org/go_elite) showed that the gene changes shared by VE, G12D, and G12D/LV (Supplemental Table S3 ) were enriched for those involved in inactivation of the MAPK pathway, although this was not quite statistically significant (P = 0.0574, adjusted for multiple hypothesis testing); presumably, this occurs as a response to hyperactivation of the Mek/Erk pathway in these cells (Fig. 4B) . No other enrichments were observed in other data sets except for gene changes unique to G12D/ LV that showed a preponderance for genes involved in RNA binding and translation (Supplemental Table S4 ). Cold
Braf signals through Braf and Craf Impaired-activity BRAF mutants are known to transactivate CRAF (Wan et al. 2004; Kamata et al. 2010) . To assess whether this is also the case for intermediate-activity mutants, Craf activity was assessed in LV MEFs and lungs and compared with wild-type as well as VE, G12D, and G12D/LV samples. Craf activity was significantly elevated by ;5.4-fold and ;1.7-fold in the LV lungs and MEFs, respectively, compared with wild-type samples, while Craf activity was not significantly elevated in the VE samples (Fig. 7A,B) . The kinase activities of both Braf and Craf were slightly elevated by G12D, but there was striking induction of Craf activity in the G12D/LV lungs and MEFs of ;20-fold and ;8.7-fold, respectively (Fig. 7A,B) . Craf and Braf siRNA was performed on immortalized MEFs to identify the contribution of each isoform to downstream Mek/Erk activation. As previously determined for cells expressing V600E Braf, siRNA knockdown of Braf but not Craf significantly suppressed Mek phosphorylation (Fig. 7C) . In G12D cells, Craf or Braf siRNA alone significantly suppressed Mek phosphorylation, although there was a greater suppression following combined Braf/Craf siRNA knockdown (Fig. 7C) . The LV and G12D/LV cells responded in a way similar to the G12D cells. In several cases, alterations in phospho-Erk levels did not always correlate with phospho-Mek levels; this is likely attributable to changes in expression of Dusps arising as a result of Braf/Craf down-regulation. Craf kinase activities for wild-type samples; (*) P < 0.01; (**) P < 0.005; (NS) not significant. (C) Immortalized MEFs of each genotype were transfected with scrambled (Scr) siRNA or Craf, Braf, or both siRNAs, and Western blots were analyzed with the antibodies indicated. Quantification of Mek/Erk phosphorylation following siRNA treatment is shown in the graphs on the right. P-Mek and P-Erk levels were normalized to Erk2, and the fold changes compared with Scrtreated samples are shown, where error bars indicate the SEM. Data were pooled from three experiments. (D) Immortalized MEFs of each genotype were treated with carrier (C), U0126 (U0), PD184352 (PD), PLX4720 (PLX), or SB590885 (885) for 4 h, and Western blots were analyzed with the antibodies indicated. Quantification of Mek/Erk phosphorylation following RAF inhibitor treatment is shown in the graphs below. P-Mek and P-Erk levels were normalized to Erk2, and the fold changes compared with carriertreated samples are shown, where error bars indicate the SEM. Data were pooled from six samples, representing three different cell lines of each genotype treated with PLX4720 or SB590885. For Western blot quantitations in C and D, P-values were calculated using the Student's t-test; (*) P < 0.01; (**) P < 0.005; (***) P < 0.001. (E) Craf:Braf heterodimer formation. LV and G12D/LV MEFs were treated with either PD184352/PLX4720 (P/X) or carrier control (C), protein lysates were harvested and immunoprecipitated for Braf, and immunoprecipitates were analyzed for Braf and Craf. As a control, the G12D/LV samples were also immunoprecipitated without (À) primary antibody and analyzed with the same antibodies. 2011), and MEK inhibitors have proven effective at ameliorating disease phenotypes in RASopathy models (Schuhmacher et al. 2008; Anastasaki et al. 2009 ). Human cancer and RASopathy cell lines with the L597V BRAF mutation are not currently available, and so we analyzed BRAF/MEK inhibitor responses using mouse cells. Each of the immortalized LV, VE, G12D, and G12D/LV MEFs was treated with either MEK inhibitors (U0126 and PD184352) or two ATP competitive RAF inhibitors (PLX4720 and SB590885). Mek/Erk activity was blocked in all cell lines in response to the MEK inhibitors (Fig.  7D) . RAF inhibitors significantly suppressed Mek/Erk phosphorylations in the VE cells, as expected, but Mek/ Erk phosphorylations were significantly induced in the LV, G12D, and G12D/LV cells (Fig. 7D) . Like WT BRAF, L597V BRAF formed a heterodimer with CRAF in HEK293 T cells following transient transfection (Supplemental Fig.  S7 ), and furthermore, heterodimer formation between endogenous Braf and Craf was strongly induced in LV and G12D/LV MEFs following dual treatment of these cells with PLX4720 and PD184352 (Fig. 7E ).
RAF inhibitors induce paradoxical Mek/Erk activation
Discussion
The L597V BRAF mutation is a relatively unique mutation because it is acquired somatically in cancer samples yet is also mutated in RASopathy conditions. Here we identified the molecular basis for the involvement of the mutation in these two pathologies. Using a knock-in mouse model, we show that
L597V
Braf can induce weak activation of the Mek/Erk pathway and that this is sufficient to drive RASopathy hallmarks but not cancer. L597V Braf only contributes to cancer when it is coexpressed with another oncogenic mutation, and in this study we demonstrate a modifying effect on G12D Krasdriven oncogenesis. We also found that RAF inhibitors induce paradoxical activation of the Mek/Erk pathway in L597V Braf mutant cells, cautioning against the use of vemurafenib/PLX4032 or other similar RAF inhibitors in the treatment of RASopathies or cancers carrying the mutation.
L597V BRAF is the best-characterized mutation affecting residue L597. Previous studies have shown that it has intermediate kinase activity when overexpressed in COS cells (Wan et al. 2004) , and, using endogenous expression from one allele of Braf, we confirmed the intermediate nature of L597V Braf and its weak impact on the Mek/ Erk pathway (Fig. 2) . The fact that RASopathy hallmarks can be induced by L597V Braf but not cancer suggests that activation of downstream signaling pathways, particularly the Mek/Erk pathway, needs to pass a key threshold for transformation to occur.
L597V BRAFand presumably other BRAF mutations present in RASopathies-clearly cannot activate downstream pathways past this point. For cancer, acquisition of a second mutation is a requirement for tipping the balance, and this may explain why L597 BRAF mutations are coincident with other low MEK/ERK-activating mutants such as S259A CRAF in occasional human cancers in addition to driver oncogenes with higher activity toward the MEK/ ERK pathway (http://www.sanger.ac.uk/perl/genetics/ CGP/cosmic). BRAF mutant human RASopathy patients (Sarkozy et al. 2009; Tidyman and Rauen 2009) and L597V Braf-expressing mice show some predisposition to cancer when aged (Supplemental Table S1 ); such lesions may arise as a result of ''second hits'' being acquired in genes that allow the transforming threshold to be surpassed.
It has been estimated that only seven to 15 somatic mutations in key ''driver'' genes are absolutely required for tumor development (Beerenwinkel et al. 2007) , with the remainder being ''passenger'' mutations or bystanders that do not contribute to the carcinogenesis process. However, this is likely to be a gross oversimplification, since it does not account for the existence of genetic interactions that can modify drivers through epistatic mechanisms (Ashworth et al. 2011) . While it is difficult to functionally prove the existence of such modifiers in human cancers, recent data from a transposon screen for genes involved in promoting Apc-driven intestinal tumorigenesis identified modifiers of the canonical Wnt pathway (March et al. 2011 ). We also previously described a functional interaction between the impaired-activity D594A Braf mutation and oncogenic Kras in the induction of rapid onset melanoma in mice (Heidorn et al. 2010; Kamata et al. 2010) . In this study, we characterized the intermediate-activity Braf mutant L597V Braf and found that it falls into the category of ''epistatic modifier,'' as it does not act as an oncogenic driver by itself but is able to interact with G12D Kras to induce high levels of signaling through the Mapk pathway as well as through Mapkindependent pathways. L597V Braf induces a shift from AAH to adenoma lesions in the G12D Kras mutant lung (Fig. 5) . Since adenomas are thought to arise through increased proliferation of AAH followed by the induction of senescence (Kerr 2001; Dankort et al. 2007) , these data suggest that L597V Braf enhances the proliferation/senescence of G12D Kras mutant alveolar type II pneumocytes in vivo. Similarly, morphological transformation and growth of G12D Kras MEFs are more similar to that driven by V600E Braf when coexpressed with L597V Braf (Fig. 4) . All in all, L597V Braf induces a partial transition from a G12D Kras mutant phenotype to a more V600E Braf-like phenotype, as confirmed at the molecular level by microarray analysis (Fig.  6 ). This is thought to be partly attributable to increased signaling through the Mek/Erk pathway, as together,
Braf and G12D Kras raise Mek/Erk activity levels to those similar to V600E Braf. In spite of this, the consequences for tumor development in the lung are somewhat paradoxical, as although enhanced adenoma formation is observed in the L597V Braf;
G12D Kras mutant lung compared with the G12D Kras mutant lung (Fig. 5A) , as with the V600E Braf mutant lung, there is reduced adenocarcinoma progression. Thus, the selective drive for the evolution of human cancers with both the L597V BRAF and G12D KRAS mutations must occur in the initiation stage, regardless of the consequences for subsequent cancer progression.
In addition to a transition to a more (Fig. 6D) , suggesting the activation of Mek/Erk-independent and/or Ras-independent signaling pathways. This observation may be related to the fact that Craf is strongly activated in the double-mutant cells but is weakly activated in the G12D Kras cells and is low in the V600E Braf cells (Fig. 7A,B) . Craf is known to operate through a number of Mek/Erk-independent signaling pathways (Niault et al. 2009 ), and conceivably, activation of these pathways may account for the unique sets of genes induced by
Braf combined with G12D Kras, although Craf has not previously been connected with genes involved in translation or RNA processing, which seem to be particularly enriched in this data set (Supplemental Table S4 ). Craf activity is also weakly elevated in the L597V Braf-expressing single-mutant MEFs, but these cells show a phenotype different from our previous analysis of MEFs expressing the impaired activity mutant D594A Braf (Kamata et al. 2010) . Craf transactivation in this situation was shown to lead to immortalization of MEFs associated with induction of aneuploidy, and this was reversed by Craf inhibition. The reason for the difference between the two may be related to the fact that Craf is more strongly activated by the D594A Braf mutation (approximately fivefold greater than wild-type MEFs) than the L597V Braf mutation (;1.7-fold greater than wild-type MEFs). Alternatively, we have not yet ruled out a role of suppressed Braf activity in contributing to the evolution of aneuploidy in D594A Braf-expressing cells. Throughout this study, we found that there was a good correlation between Raf activity and levels of Mek phosphorylation, but Erk phosphorylation was more variable. As demonstrated in other studies (Pratilas et al. 2009 ), this is related to the expression of Dusp6 and Sprouty2, negative regulators of the Mek/Erk pathway. Both are transcriptional targets of the pathway (Packer et al. 2009; Pratilas et al. 2009 ), and Sprouty2 has been shown to act as a tumor suppressor at least in the context of G12D Kras-mediated lung tumorigenesis (Shaw et al. 2007 ). Dusp6 is a dual-specificity phosphatase that acts downstream from Mek to inactivate Erk (Keyse 2008) , whereas Sprouty2 acts at multiple levels of the Erk pathway, one way being through direct interaction with Raf (Kim and Bar-Sagi 2004) . In MEFs and the lung,
V600E
Braf expression was found to induce very high levels of expression of these proteins (Figs. 2, 3) , whereas
L597V
Braf did not at all, indicating higher Erk pathway output by
V600E
Braf and no feedback inhibition in the L597V Braf cells. Although levels of phospho-Mek were significantly higher in the V600E Braf mutant cells, phospho-Erk levels were similar in the two. This suggests that the pathway is sensitive to feedback inhibition below Mek at the level of Erk in the V600E Braf mutant cells, presumably through the action of Dusps, but insensitive to feedback inhibition upstream of Mek. The mechanism of insensitivity upstream of Mek may be related to the fact that the active Braf kinase conformation of V600E Braf cannot bind to Sprouty2 (Brady et al. 2009 ). Regardless of the mechanism, feedback regulation of the Erk pathway offers exquisite control of the pathway and is important in regulation of the ultimate biological outputs of the pathway.
Using siRNA, we show that L597V Braf activates the Mek/Erk pathway through its intrinsic Braf kinase activity as well as through transactivation of Craf on both the WT Kras and G12D Kras backgrounds (Fig. 7C ). This is a scenario similar to G12D Kras cells expressing WT Braf and WT Craf (Blasco et al. 2011; Karreth et al. 2011 ) but different from cells expressing V600E Braf that signal entirely through its intrinsic activity. As with WT Braf, the likely mechanism for Craf transactivation by
L597V
Braf is through dimerization, membrane localization, and interaction with Ras.GTP. Given this observation, it is not surprising that ATP-competitive RAF inhibitors (PLX4720 and SB590885) activate the Mek/Erk pathway in L597V Braf mutant cells (Fig. 7D) BRAF, do not. It will be interesting to assess what threshold of BRAF activity is required to allow response to vemurafenib, and related to this is the question of whether mutant BRAF isoforms undergo dimerization and the levels of RAS activation achieved in cells with different levels of BRAF activity.
Materials and methods
Mouse strains and genotyping
All animal experiments were carried out under U.K. Home Office License authority. Braf +/LSL-L597V mice were generated in the same way as Braf +/LSL-V600E (Mercer et al. 2005) and Braf +/LSL-D594A (Heidorn et al. 2010; Kamata et al. 2010) mice, except Braf exon 15 contained the C1789A mutation. The Kras +/LSL-G12D mice were as previously reported (Jackson et al. 2001 ) and were obtained from the Mouse Models of Human Cancers Consortium (MMHCC) Mouse Repository (http://www.nih.gov/science/models/mouse/ resources/mmhcc.html). All strains were maintained by backcrossing onto the C57BL6J background, and phenotype analysis was performed for mice that had been maintained for more than five generations on this background strain. Genotyping of Braf , and Cre alleles was performed using the primer systems previously reported (Mercer et al. 2005) . The Kras LSL-G12D allele was genotyped using primers 59-AGCTAGCCACCATGGCTTGAGTA AGTCTGCA-39 and 59-CCTTTACAAGCGCACGCAGATGTA GA-39. To monitor Cre recombination, the Kras Lox-G12D allele was genotyped with primers 59-TGACACCAGCTTCGGCTTCCT-39 and 59-TCCGAATTCAGTGACTACAGATGTACAGA-39. Infection of lungs with AdCre (University of Iowa) was performed as described (Jackson et al. 2001; Dankort et al. 2007 ).
Histology and tissue staining
Tissues were processed for histology and stained as described (Mercer et al. 2005) . For cardiomyocyte analysis, cell membranes were stained with FITC-conjugated wheat germ agglutinin (WGA) (Sigma). For quantification, H&E-and WGA-stained
